603896.SH
寿仙谷
SSE · Healthcare · Biotechnology · CN
CNY 14.78
−1.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 625.3M | 640.2M | 705.1M | 784.3M | 829.1M |
| Cost of Revenue | 139.0M | 136.6M | 140.0M | 135.5M | 129.2M |
| Gross Profit | 486.3M | 503.6M | 565.1M | 648.8M | 699.9M |
| Operating Expenses | |||||
| R&D Expense | 51.7M | 51.6M | 48.4M | 49.7M | 47.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 104.2M | 100.9M | 88.4M | 87.0M | 85.8M |
| Selling & Marketing Expense | 248.3M | 262.8M | 309.5M | 316.8M | 319.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 430.3M | 435.6M | 435.8M | 439.3M | 448.1M |
| Cost and Expenses | 569.3M | 572.2M | 575.8M | 574.9M | 577.3M |
| Operating Income (EBIT) | 102.9M | 127.0M | 175.0M | 254.7M | 280.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 73.7M | 102.1M | 174.5M | 254.9M | 278.0M |
| Income Tax Expense | 85.3M | 84.0M | 45.0K | 430.9K | 452.6K |
| Bottom Line | |||||
| Net Income | (11.6M) | 18.2M | 174.4M | 254.5M | 277.8M |
| Earnings from Cont. Ops | (11.6M) | 18.1M | 174.4M | 254.5M | 277.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.6M) | 18.2M | 174.4M | 254.5M | 277.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.05) | CN¥0.09 | CN¥0.88 | CN¥1.30 | CN¥1.43 |
| Diluted EPS | (CN¥0.05) | CN¥0.09 | CN¥0.88 | CN¥1.30 | CN¥1.43 |
| Revenue Per Share | CN¥3.24 | CN¥3.17 | CN¥3.56 | CN¥4.01 | CN¥4.27 |
| Shares | |||||
| Basic Shares Outstanding | 192.9M | 201.9M | 198.2M | 195.8M | 194.3M |
| Diluted Shares Outstanding | 192.9M | 201.9M | 198.2M | 195.8M | 194.3M |
| Profitability Metrics | |||||
| EBITDA | — | 234.2M | 268.9M | 345.0M | 354.9M |
| D&A | — | 107.2M | 93.9M | 90.3M | 74.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026